Status:
COMPLETED
Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
Lead Sponsor:
R-Pharm
Conditions:
Advanced Solid Tumors
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.
Eligibility Criteria
Inclusion
- Recovery from surgery or radiation therapy
- Measurable or non-measurable disease
- Available for follow-up
Exclusion
- Neuropathy
- Uncontrolled pulmonary or cardiovascular disease
- Known history of HIV infection
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00207129
Start Date
October 1 2004
End Date
December 1 2005
Last Update
January 30 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
San Antonio, Texas, United States